Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.
Patients with SLE experience a severely impaired HRQoL, despite effective therapy. However, HRQoL and symptoms that constitute major concerns for SLE patients, such as fatigue, are not included among the components of the most used disease activity instruments. Thus, the impact of biological therapies on HRQoL have to be drawn in an independent manner.